Paul Hastings Advised Underwriters on Humacyte’s $40 Million Public Offering
Paul Hastings LLP advised TD Cowen, Cantor and BTIG in connection with Humacyte, Inc’s., underwritten public offering of 13,400,000 shares of common stock at $3.00 per share. The gross proceeds are expected to be approximately $40.2 million. In addition, Humacyte has granted the underwriters an option for a period of 30 days to purchase up to an additional 2,010,000 shares of Humacyte’s common stock at the public offering price, less underwriting discounts and commissions. Humacyte, Inc., (Nasdaq: HUMA) is a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale.
Partner and co-chair of Equity Capital Markets and co-chair of the Corporate Life Sciences Group Seo Salimi and Capital Markets Partner Will Magioncalda led the Paul Hastings team, which included associates Chris Guerin and Adam Swank.
More details on the transaction can be found here.
With widely recognized elite teams across 18 core practices, Paul Hastings is a premier law firm with a culture of excellence focused on providing intellectual capital and superior execution globally to the world's leading investment banks, asset managers and corporations.